12.3 Respiratory Muscle Strength (MIP/MEP/CPF)

Respiratory Muscle Strength on the RPFT Blueprint

Domain II includes respiratory muscle pressure measurements under II.A.17 (select), II.B.17 (perform), and II.C.17 (evaluate validity). These tests answer a different question from spirometry: not “how fast and how much volume can move,” but “how hard can the pump pull and push against an occlusion,” plus, for cough peak flow, “how effective is the cough expiratory flow for airway clearance.”

MIP and MEP: Definitions and Physiology

| Test | Also called | What it measures | Typical starting lung volume concept | |---|---|---| | MIP | PImax, maximal inspiratory pressure | Strength of inspiratory muscles (diaphragm and accessories) as negative mouth pressure | Near RV or residual volume region (maximal inspiratory effort from low lung volume) per protocol | | MEP | PEmax, maximal expiratory pressure | Strength of expiratory muscles (abdominals and internal intercostals) as positive mouth pressure | Near TLC (maximal expiratory effort from high lung volume) per protocol |

Pressures are reported in cm H₂O. MIP is a negative number (e.g., −80 cm H₂O); many reports also discuss magnitude. MEP is positive (e.g., +120 cm H₂O). Low |MIP| or low MEP supports inspiratory or expiratory muscle weakness when technique is valid.

Reference equations depend on age, sex, and sometimes posture; the RPFT must obtain a technically valid value and apply the lab’s reference set—not memorize every predicted number.

Technique (II.B.17)

Equipment and interface

• Calibrated pressure transducer / manometer system with known accuracy
• Flanged mouthpiece (or manufacturer-specified rigid mouthpiece) that the patient can seal with lips
• Nose clip mandatory—nasal leak destroys the pressure plateau
• Small leak or pressure-relief features may exist on some devices to reduce glottic closure artifact—know your device IFU
• Patient seated upright unless order/SOP specifies otherwise; hands may need to support the cheeks

MIP (PImax) performance steps

1. Explain: “Empty your lungs, seal tightly, then pull in hard against the blocked tube and hold the pressure.”
2. Apply nose clip; insert flanged mouthpiece; coach lip seal over the flange.
3. Patient exhales toward residual volume (per protocol).
4. Occlusion engages; patient generates maximal inspiratory effort.
5. Sustain pressure for the required plateau (commonly on the order of 1–3 seconds of relatively stable peak—follow SOP).
6. Rest between efforts to avoid fatigue false lows.
7. Repeat for the required number of trials.

MEP (PEmax) performance steps

1. Explain: “Fill your lungs all the way, seal tightly, then blow out hard against the blocked tube and hold.”
2. Nose clip on; firm flange seal; cheeks supported (patient or technologist) to reduce buccal ballooning.
3. Patient inhales to near TLC.
4. Occlusion; maximal expiratory effort; sustain plateau per protocol.
5. Multiple trials with rest.

Number of efforts and repeatability

Labs typically obtain at least three acceptable efforts (often more if variability is high), aiming for a tight cluster of the best values (e.g., the highest pressures agreeing within a defined cm H₂O or percentage—use ATS/ERS-aligned or lab criteria). Report the maximum acceptable MIP and MEP (most negative MIP magnitude and highest MEP) meeting quality rules, not the average of obviously leaked trials.

Fatigue matters: endless poorly coached trials can worsen true maximal pressures. Quality coaching early beats twenty exhausted attempts.

Common Leaks and Artifacts (II.C.17)

Validity review: inspect the pressure–time tracing for a rapid rise to a sustained plateau. Reject trials with early leak collapse, cough, or laughing. If the best of many trials still shows leak morphology, do not report a falsely low “weakness” without comment.

Cough Peak Flow (CPF)

Cough peak flow is the peak expiratory flow achieved during a maximal cough maneuver, measured with a peak flow meter or spirometer-capable system per lab method. It is used as a practical index of cough effectiveness for secretion clearance.

Clinical contexts

• Neuromuscular disease (ALS, muscular dystrophy, myasthenia, Guillain-Barré recovery): weak cough → secretion retention, atelectasis, infection risk
• Extubation readiness / critical care pathways (when ordered in the PFT or bedside lab scope): low CPF suggests inadequate cough for airway clearance after tube removal—thresholds are protocol-specific (commonly discussed cut-points in the clinical literature; follow the ordering service’s criterion rather than inventing one)
• Pre/post interventions such as mechanical insufflation–exsufflation training outcomes when the lab participates in that monitoring

Performing CPF

1. Patient seated if possible; explain a true cough, not a gentle huff only (unless protocol specifies assisted cough).
2. Inhale deeply; cough forcibly into the meter/mouthpiece with tight seal.
3. Record peak flow; perform multiple trials; report best acceptable effort.
4. Note if cough is painful, weak, or wet; coordinate with clinical team for suctioning needs if secretions mobilize during testing.

CPF is not a substitute for MIP/MEP; it answers cough flow effectiveness, while pressures answer static muscle strength. Many neuromuscular protocols include both.

Neuromuscular and Other Applications (II.A.17)

Select respiratory muscle strength testing when:

Do not select maximal pressures as a routine add-on for every simple spirometry visit without indication—selection skill includes appropriateness.

Contraindications/cautions: acute unstable angina, recent eye surgery or other conditions where high intrathoracic/vascular pressure swings are unsafe per policy, active hemoptysis, severe uncontrolled hypertension, inability to seal, and orders to avoid forced efforts. Coordinate with the ordering provider when risk is unclear.

Putting Validity Together (II.C.17)

Before release:

1. Were nose clip and flange seal used?
2. Were starting volumes coached correctly?
3. Is there a sustained plateau on the best efforts?
4. Do top trials meet repeatability, or is only one outlier “best” after leaks?
5. Were cheeks supported on MEP?
6. For CPF, was the maneuver a maximal cough with acceptable peak capture?
7. Are results consistent with the clinical picture, or do they scream technical failure (e.g., MEP of 20 cm H₂O in a muscular asymptomatic athlete with perfect technique notes missing)?

Report limitations clearly when the patient cannot seal due to facial weakness—the finding may still be clinically informative if documented as “unable to seal; pressures may underestimate true capacity” versus silently posting a devastating number.

Clinical Scenario

A 54-year-old with ALS has declining FVC and is referred for MIP, MEP, and CPF. Selection (II.A.17): full muscle-strength and cough-flow set. Performance (II.B.17): flanged mouthpiece, nose clip, three-plus MIP efforts from low volume with visual feedback; MEP with cheek support from TLC; three maximal coughs for CPF. First MEP trials show buccal ballooning and a 40 cm H₂O under-read; re-coach hands-on-cheeks and obtain repeatable higher values. Validity (II.C.17): accept the improved cluster with plateaus; note mild facial weakness affecting seal on early trials. CPF is reduced versus prior visit—communicated to the clinical team for secretion-management planning.

Link to Practice

/practice/rpftPractice questions with detailed explanations